おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Biohaven Pharmaceutical
company
About
Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
- 1001 - 5000
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $80M
- Industries
- Biotechnology,Health Care,Health Diagnostics,Neuroscience,Pharmaceutical
- Founded date
- Jan 1, 2013
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
- Sub-Organizations
-
BioShin
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$80M
Biohaven Pharmaceutical has raised a total of
$80M
in funding over 2 rounds. Their latest funding was raised on
Nov 1, 2016 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 1, 2016 | Series Unknown | $80M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Biohaven Pharmaceutical is funded by 2 investors.
Litmore Capital
and Knoll Capital Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series Unknown |
|
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
